Breaking News

ANI Pharma Acquires Two NDAs from Merck for $75M

January 6, 2016

Adds purified corticotropin gel and corticotropin zinc hydroxide to its portfolio

ANI Pharmaceuticals Inc. has completed the acquisition of the NDAs for purified corticotropin gel and corticotropin zinc hydroxide from Merck for $75 million in cash and a percentage of future net sales. The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands-based wholly owned indirect subsidiary of ANI.

Arthur Przybyl, president and chief executive officer, ANI Pharmaceuticals said, “Having now closed the acquisition of the corticotrophin NDAs, we look forward to advancing our re-commercialization plan.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks